Global B-Cell Chronic Lymphocytic Leukemia Therapeutics Development Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter-strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. B-Cell Chronic Lymphocytic Leukemia Overview
  3. Therapeutics Development
  4. Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview
  5. Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis
  6. B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies
  7. B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes
  8. B-Cell Chronic Lymphocytic Leukemia Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies
  13. B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes
  14. B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
  • AB Science SA
  • Amgen Inc.
  • Celgene Corporation
  • Dynavax Technologies Corporation
  • Eisai Co., Ltd.
  • ElsaLys Biotech SAS
  • F. Hoffmann-La Roche Ltd.
  • iDD biotech SAS
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Molecular Templates Inc.
  • Noxxon Pharma AG
  • Ono Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • TheraMAB LLC
  • Unum Therapeutics, Inc.

For more information visit http://www.researchandmarkets.com/research/hx55d6/bcell_chronic.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716